Literature DB >> 2938344

Peptide neuroregulators: the opioid system as a model.

J D Barchas, C Evans, G R Elliott, P A Berger.   

Abstract

Aaron Lerner's work provides a stunning set of examples of substances that help to transmit information in the brain and body. His characterization of alpha-MSH and melatonin and his sparking of interest in the further discovery of previously unknown substances have been of inestimable value for the field of neurobiology. Efforts such as those that Lerner undertook so successfully in the field of investigative dermatology now constitute a major research thrust in the field of behavioral neurochemistry and are directly related to advances in psychiatry and neurology. This review considers aspects of research on the neuropeptides, with particular attention to the endogenous opioid (morphine-like) peptides that are active on neural tissue. Neuropeptide research can be categorized broadly as efforts to discover and characterize new families and classes of active agents, investigations of their genetic and molecular processing, and studies of their relationships to behavior in animals and human beings. This review selectively considers some key research questions and strategies that arise from such research.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2938344      PMCID: PMC2589971     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  106 in total

1.  Isolation and structure of an untriakontapeptide with opiate activity from camel pituitary glands.

Authors:  C H Li; D Chung
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

2.  Hemodialysis in schizophrenia: three failures with chronic patients.

Authors:  H M Emrich; W Kissling; M Fischler; D V Zerssen; H Riedhammer; H H Edel
Journal:  Am J Psychiatry       Date:  1979-08       Impact factor: 18.112

3.  Naloxone in schizophrenia: negative result.

Authors:  J Lipinski; R Meyer; C Kornetsky; B M Cohen
Journal:  Lancet       Date:  1979-06-16       Impact factor: 79.321

4.  Synthetic enkephalin analogue in treatment of schizophrenia.

Authors:  A Jørgensen; R Fog; B Veilis
Journal:  Lancet       Date:  1979-04-28       Impact factor: 79.321

5.  Studies of beta-endorphin in psychiatric patients.

Authors:  P A Berger; J D Barchas
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

6.  Naloxone-induced reduction of schizophrenic symptoms.

Authors:  H A Jørgensen; C Cappelen
Journal:  Acta Psychiatr Scand       Date:  1982-05       Impact factor: 6.392

7.  Human EEG response to beta-endorphin.

Authors:  A Pfefferbaum; P A Berger; G R Elliott; J R Tinklenberg; B S Kopell; J D Barchas; C H Li
Journal:  Psychiatry Res       Date:  1979-07       Impact factor: 3.222

8.  Des-tyrosine-gamma-endorphin administration in chronic schizophrenics. A preliminary report.

Authors:  C A Tamminga; P J Tighe; T N Chase; E G DeFraites; M H Schaffer
Journal:  Arch Gen Psychiatry       Date:  1981-02

Review 9.  Analysis of pro-opiomelancortin gene structure and function.

Authors:  J H Eberwine; J L Roberts
Journal:  DNA       Date:  1983

10.  Profound analgesic effects of beta-endorphin in man.

Authors:  T Oyama; T Jin; R Yamaya; N Ling; R Guillemin
Journal:  Lancet       Date:  1980-01-19       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.